Efficacy and Safety of a New Leuprolide Acetate 22.5 mg Depot Formulation in the Treatment of Prostate Cancer.
Phase of Trial: Phase III
Latest Information Update: 06 Mar 2017
At a glance
- Drugs Leuprorelin (Primary)
- Indications Prostate cancer
- Focus Registrational; Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 12 May 2015 According to GP Pharm media release, Lutrate Depot 22.5 mg was approved through an EU Decentralized procedure.
- 26 Aug 2013 Planned End Date changed from 1 Jun 2013 to 1 Aug 2013 as reported by ClinicalTrials.gov.